Comparative Adverse Effect Profiles of Platinum Drugs
- 1 October 1995
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 13 (4) , 228-244
- https://doi.org/10.2165/00002018-199513040-00003
Abstract
Since the discovery of the biologically active platinum complexes 30 years ago, 2 agents have become widely established in clinical oncology practice. Both cisplatin and carboplatin are platinum(II)...Keywords
This publication has 99 references indexed in Scilit:
- Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetronEuropean Journal Of Cancer, 1992
- Neurotoxic side-effects of cisplatinEuropean Journal of Cancer and Clinical Oncology, 1991
- Clinical Pharmacokinetics of CarboplatinClinical Pharmacokinetics, 1991
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingNew England Journal of Medicine, 1990
- Cisplatin NeurotoxicityNew England Journal of Medicine, 1990
- Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian CancerNew England Journal of Medicine, 1990
- The late effects of cis-platinum on renal functionEuropean Journal of Cancer and Clinical Oncology, 1989
- On the receiving end—patient perception of the side-effects of cancer chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1983
- The inhibition of renal ATPase by cisplatin and some bio-transformation productsChemico-Biological Interactions, 1982